Biotech

Innovent Biologics teams with Takeda on global IO therapies

Innovent Biologics and Takeda are teaming up. This global partnership seeks to accelerate the development and launch of Innovent’s new immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies. The partnership aims to provide groundbreaking cancer treatments to patients everywhere. It uses the combined skills of both companies. The collaboration highlights three main investigational therapies from Innovent’s IO+ADC pipeline. IBI363 is a first-in-class bispecific antibody fusion protein that targets PD-1 and IL-2α. It shows strong anti-tumor effects. It's a hopeful new therapy for immuno-oncology. IBI363 is now in global Phase 3 development. It targets second-line squamous non-small cell lung cancer (sqNSCLC). It has received Breakthrough Designation from China’s NMPA and Fast Track Designation from the U.S. FDA. Innovent and Takeda will work together to develop IBI363 globally. They will split the development…